1. Chew EY, Ferris III FL. "Nonproliferative diabetic retinopathy," in Ryan SJ, ed., Retina. St. Louis: Mosby, 2001. pp. 1295-1308.

2. Klein R and Klein BEK. "Epidemiology of eye disease in diabetes," in Flynn HW and Smiddy WE, eds., Diabetes and Ocular Disease: Past, Present, and Future Therapies. American Academy of Ophthalmology, 2000. pp.19-61.

3. Moss SE, Klein R, Klein BEK. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101:1061-1070.

4. Kostraba NJ, Klein R, Dorman JS, et al. The epidemiology of diabetes complications study, IV: correlates of diabetic background and proliferative retinopathy. Am J Epidemiol 1991;133:381-391.

5. Chiang YP, Bassi LJ, Javitt JC. Federal budgetary costs of blindness. Milbank Q 1992;70:319-340.

6. Ferris III FL, Davis MD, Aiello LM, Chew EY. "Clinical studies on treatment for diabetic retinopathy," in Flynn HW and Smiddy WE, eds., Diabetes and Ocular Disease: Past, Present and Future Therapies. American Academy of Ophthalmology, 2000. pp. 81-99.

7. Davis MD, Blodi BA. "Proliferative diabetic retinopathy," in Ryan SJ, ed., Retina. St. Louis: Mosby, 2001. pp. 1309-1349.

8. Frank RN, "Etiologic mechanisms in diabetic retinopathy," in Ryan SJ, ed., Retina. St. Louis: Mosby, 2001. pp. 1259-1294.

9. Gardner TW, Aiello LP. "Pathogenesis of diabetic retinopathy," in Flynn HW and Smiddy WE, eds., Diabetes and Ocular Disease: Past, Present and Future Therapies. American Academy of Ophthalmology, 2000. pp. 1-17.

10. Folk JC and Oh KT. "Photocoagulation for diabetic macular edema and diabetic retinopathy," in Flynn HW and Smiddy WE, eds., Diabetes and Ocular Disease: Past, Present and Future Therapies. American Academy of Ophthalmology, 2000. pp. 115-153.

11. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.

12. Simo R, Lecube A, Segura RM, et al. Free insulin growth factor-1 and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol 2002;134(3):376-382.

13. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109(5):920-927.

14. Aiello LP, Gardner TW. "Future therapies for diabetic retinopathy," in Flynn HW and Smiddy WE, eds., Diabetes and Ocular Disease: Past, Present and Future Therapies. American Academy of Ophthalmology, 2000. pp. 239-273.

15. Henricsson M, Nystrom L, Blohme G, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 2003;26(2):349-354.

16. Preferred Practice Patterns Committee, Retina Panel. Diabetic Retinopathy. American Academy of Ophthalmology, 1998.